IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v6y2015i1d10.1038_ncomms8227.html
   My bibliography  Save this article

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

Author

Listed:
  • Madhuri Kalathur

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
    Faculty of Biology and Medicine, University of Lausanne (UNIL)
    Present address: Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA)

  • Alberto Toso

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Jingjing Chen

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
    Faculty of Biology and Medicine, University of Lausanne (UNIL))

  • Ajinkya Revandkar

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
    Faculty of Biology and Medicine, University of Lausanne (UNIL))

  • Claudia Danzer-Baltzer

    (Institute of Physiology, University of Zurich
    Zurich Center for Integrative Human Physiology, University of Zurich
    Competence Center for Systems Physiology and Metabolic Diseases)

  • Ilaria Guccini

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Abdullah Alajati

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Manuela Sarti

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Sandra Pinton

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Lara Brambilla

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Diletta Di Mitri

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Giuseppina Carbone

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • R Garcia-Escudero

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Alessandro Padova

    (IRBM Science Park S.p.A.)

  • Letizia Magnoni

    (Siena Biotech Spa)

  • Alessia Tarditi

    (Siena Biotech Spa)

  • Laura Maccari

    (Siena Biotech Spa)

  • Federico Malusa

    (Siena Biotech Spa)

  • Ravi Kiran Reddy Kalathur

    (Experimental & Clinical Cell Therapy Institute, Spinal Cord & Tissue Regeneration Center Salzburg, Paracelsus Medizinische Privatuniversität)

  • Lorenzo A. Pinna

    (University of Padova, and VIMM)

  • Giorgio Cozza

    (University of Padova, and VIMM)

  • Maria Ruzzene

    (University of Padova, and VIMM)

  • Nicolas Delaleu

    (Broegelmann Research Laboratory, University of Bergen)

  • Carlo V. Catapano

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI))

  • Ian J. Frew

    (Institute of Physiology, University of Zurich
    Zurich Center for Integrative Human Physiology, University of Zurich
    Competence Center for Systems Physiology and Metabolic Diseases)

  • Andrea Alimonti

    (Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI)
    Faculty of Biology and Medicine, University of Lausanne (UNIL))

Abstract

Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3–CK2–PML network that can be targeted for pro-senescence therapy for cancer.

Suggested Citation

  • Madhuri Kalathur & Alberto Toso & Jingjing Chen & Ajinkya Revandkar & Claudia Danzer-Baltzer & Ilaria Guccini & Abdullah Alajati & Manuela Sarti & Sandra Pinton & Lara Brambilla & Diletta Di Mitri & G, 2015. "A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours," Nature Communications, Nature, vol. 6(1), pages 1-12, November.
    • Handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8227
    DOI: 10.1038/ncomms8227
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms8227
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms8227?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8227. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.